Quick Answer
Aardvark Therapeutics, Inc. reported Stockholders Equity of $106.63 million for the year ending 2025.
- Aardvark Therapeutics, Inc. showed an increase of +295.1% in Stockholders Equity from 2024 to 2025.
- This data is from Aardvark Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$36.91 million | Q2 2024: -$42.31 million | Q3 2024: -$46.17 million | Q1 2025: $150.69 million | Q2 2025: $136.93 million | Q3 2025: $122.38 million.
- Over the full 3 years of available data (2023 to 2025), Aardvark Therapeutics, Inc.'s Stockholders Equity has grown by 406.4%.
- Historical annual values: Fiscal year 2025: $106.63 million | Fiscal year 2024: -$54.64 million | Fiscal year 2023: -$34.80 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: